
Zanidatamab Displays Safety, Efficacy in HER2-Expressing Gastric Cancer
Zanidatamab-hrii (Ziihera) with or without chemotherapy displayed a manageable safety profile and favorable efficacy outcomes in heavily pretreated patients with HER2-expressing gastroesophageal adenocarcinoma (GEA), according to results from a dose- …